Edward Ayoub

This study uses spatial proteomics to reveal that TP53 mutant AML residual disease forms immunosuppressive niches in the bone marrow, segregated from T-cells, suggesting niche-level immune evasion.

This study identifies that macrophage-secreted pyrimidine metabolites confer chemotherapy resistance in AML by inhibiting drug activation, and shows that targeting macrophage metabolism can restore drug sensitivity.

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

This paper identifies a novel MYC-GSPT1 feedback loop and reports a dual degrader, GT19630, that effectively targets MYC-driven cancers with anti-proliferative and apoptotic effects.